Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study

Autores
Coban, Ahmet Yilmaz; Alakbarova, Gumral; Satti, Luqman; Tayyab, Nadia; Zaman, Gohar; Morcillo, Nora Susana; Imperiale, Belén Rocío; Wainmayer, Ingrid; Símboli, Norberto Fabián
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Effective control of tuberculosis is achieved by early diagnosis and drug susceptibility testing for initiation of appropriate treatment. The performance of crystal violet decolorization assay (CVDA) for susceptibility testing of Mycobacterium tuberculosis to isoniazid (INH) and rifampicin (RIF) was compared in a multicenter study. Methods: Seventy-two M. tuberculosis isolates were tested in two phases by CVDA. Results: In Phase I, the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and agreement for INH were 100%, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 98.2%, 100%, 94.1%, 100%, and 98.6%, respectively. In Phase II, specificity, sensitivity, PPV, NPV, and agreement were 98%, 100%, 95.4%, 100%, and 98.6% for INH, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 96.3%, 88.2%, 88.2%, 96.3%, and 94.4%, respectively. Results in the study were obtained on average 10.9 ± 3.1 days in Phase I and 9.8 ± 2.2 days in Phase II. Conclusion: CVDA can be performed for drug susceptibility testing in developed and developing countries. In addition, further studies with larger sample size are needed for evaluation of this method.
Fil: Coban, Ahmet Yilmaz. Akdeniz Üniversitesi; Turquía
Fil: Alakbarova, Gumral. Medical Microbiology Laboratory. Thalassemia Center; Azerbaiyán
Fil: Satti, Luqman. Armed Forces Institute of Pathology; Pakistán
Fil: Tayyab, Nadia. Armed Forces Institute of Pathology; Pakistán
Fil: Zaman, Gohar. Armed Forces Institute of Pathology; Pakistán
Fil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Wainmayer, Ingrid. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina
Fil: Símboli, Norberto Fabián. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina
Materia
CRYSTAL VIOLET DECOLORIZATION ASSAY
ISONIAZID
MULTIDRUG RESISTANT
MYCOBACTERIUM TUBERCULOSIS
RIFAMPICIN
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/95989
Acceder
id CONICETDig_74b9ae333f08db30da2b55c073a3774c
oai_identifier_str oai:ri.conicet.gov.ar:11336/95989
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter studyCoban, Ahmet YilmazAlakbarova, GumralSatti, LuqmanTayyab, NadiaZaman, GoharMorcillo, Nora SusanaImperiale, Belén RocíoWainmayer, IngridSímboli, Norberto FabiánCRYSTAL VIOLET DECOLORIZATION ASSAYISONIAZIDMULTIDRUG RESISTANTMYCOBACTERIUM TUBERCULOSISRIFAMPICINhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: Effective control of tuberculosis is achieved by early diagnosis and drug susceptibility testing for initiation of appropriate treatment. The performance of crystal violet decolorization assay (CVDA) for susceptibility testing of Mycobacterium tuberculosis to isoniazid (INH) and rifampicin (RIF) was compared in a multicenter study. Methods: Seventy-two M. tuberculosis isolates were tested in two phases by CVDA. Results: In Phase I, the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and agreement for INH were 100%, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 98.2%, 100%, 94.1%, 100%, and 98.6%, respectively. In Phase II, specificity, sensitivity, PPV, NPV, and agreement were 98%, 100%, 95.4%, 100%, and 98.6% for INH, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 96.3%, 88.2%, 88.2%, 96.3%, and 94.4%, respectively. Results in the study were obtained on average 10.9 ± 3.1 days in Phase I and 9.8 ± 2.2 days in Phase II. Conclusion: CVDA can be performed for drug susceptibility testing in developed and developing countries. In addition, further studies with larger sample size are needed for evaluation of this method.Fil: Coban, Ahmet Yilmaz. Akdeniz Üniversitesi; TurquíaFil: Alakbarova, Gumral. Medical Microbiology Laboratory. Thalassemia Center; AzerbaiyánFil: Satti, Luqman. Armed Forces Institute of Pathology; PakistánFil: Tayyab, Nadia. Armed Forces Institute of Pathology; PakistánFil: Zaman, Gohar. Armed Forces Institute of Pathology; PakistánFil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; ArgentinaFil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Wainmayer, Ingrid. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; ArgentinaFil: Símboli, Norberto Fabián. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; ArgentinaMedknow Publications2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/95989Coban, Ahmet Yilmaz; Alakbarova, Gumral; Satti, Luqman; Tayyab, Nadia; Zaman, Gohar; et al.; Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study; Medknow Publications; International Journal of Mycobacteriology; 7; 4; 10-2018; 310-3142212-55312212-554XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/ijmy.ijmy_141_18info:eu-repo/semantics/altIdentifier/url/http://www.ijmyco.org/article.asp?issn=2212-5531;year=2018;volume=7;issue=4;spage=310;epage=314;aulast=Cobaninfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:19:23Zoai:ri.conicet.gov.ar:11336/95989instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:19:23.615CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
title Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
spellingShingle Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
Coban, Ahmet Yilmaz
CRYSTAL VIOLET DECOLORIZATION ASSAY
ISONIAZID
MULTIDRUG RESISTANT
MYCOBACTERIUM TUBERCULOSIS
RIFAMPICIN
title_short Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
title_full Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
title_fullStr Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
title_full_unstemmed Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
title_sort Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study
dc.creator.none.fl_str_mv Coban, Ahmet Yilmaz
Alakbarova, Gumral
Satti, Luqman
Tayyab, Nadia
Zaman, Gohar
Morcillo, Nora Susana
Imperiale, Belén Rocío
Wainmayer, Ingrid
Símboli, Norberto Fabián
author Coban, Ahmet Yilmaz
author_facet Coban, Ahmet Yilmaz
Alakbarova, Gumral
Satti, Luqman
Tayyab, Nadia
Zaman, Gohar
Morcillo, Nora Susana
Imperiale, Belén Rocío
Wainmayer, Ingrid
Símboli, Norberto Fabián
author_role author
author2 Alakbarova, Gumral
Satti, Luqman
Tayyab, Nadia
Zaman, Gohar
Morcillo, Nora Susana
Imperiale, Belén Rocío
Wainmayer, Ingrid
Símboli, Norberto Fabián
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CRYSTAL VIOLET DECOLORIZATION ASSAY
ISONIAZID
MULTIDRUG RESISTANT
MYCOBACTERIUM TUBERCULOSIS
RIFAMPICIN
topic CRYSTAL VIOLET DECOLORIZATION ASSAY
ISONIAZID
MULTIDRUG RESISTANT
MYCOBACTERIUM TUBERCULOSIS
RIFAMPICIN
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Background: Effective control of tuberculosis is achieved by early diagnosis and drug susceptibility testing for initiation of appropriate treatment. The performance of crystal violet decolorization assay (CVDA) for susceptibility testing of Mycobacterium tuberculosis to isoniazid (INH) and rifampicin (RIF) was compared in a multicenter study. Methods: Seventy-two M. tuberculosis isolates were tested in two phases by CVDA. Results: In Phase I, the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and agreement for INH were 100%, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 98.2%, 100%, 94.1%, 100%, and 98.6%, respectively. In Phase II, specificity, sensitivity, PPV, NPV, and agreement were 98%, 100%, 95.4%, 100%, and 98.6% for INH, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 96.3%, 88.2%, 88.2%, 96.3%, and 94.4%, respectively. Results in the study were obtained on average 10.9 ± 3.1 days in Phase I and 9.8 ± 2.2 days in Phase II. Conclusion: CVDA can be performed for drug susceptibility testing in developed and developing countries. In addition, further studies with larger sample size are needed for evaluation of this method.
Fil: Coban, Ahmet Yilmaz. Akdeniz Üniversitesi; Turquía
Fil: Alakbarova, Gumral. Medical Microbiology Laboratory. Thalassemia Center; Azerbaiyán
Fil: Satti, Luqman. Armed Forces Institute of Pathology; Pakistán
Fil: Tayyab, Nadia. Armed Forces Institute of Pathology; Pakistán
Fil: Zaman, Gohar. Armed Forces Institute of Pathology; Pakistán
Fil: Morcillo, Nora Susana. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Imperiale, Belén Rocío. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Wainmayer, Ingrid. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina
Fil: Símboli, Norberto Fabián. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud “Dr. C. G. Malbrán”; Argentina
description Background: Effective control of tuberculosis is achieved by early diagnosis and drug susceptibility testing for initiation of appropriate treatment. The performance of crystal violet decolorization assay (CVDA) for susceptibility testing of Mycobacterium tuberculosis to isoniazid (INH) and rifampicin (RIF) was compared in a multicenter study. Methods: Seventy-two M. tuberculosis isolates were tested in two phases by CVDA. Results: In Phase I, the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and agreement for INH were 100%, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 98.2%, 100%, 94.1%, 100%, and 98.6%, respectively. In Phase II, specificity, sensitivity, PPV, NPV, and agreement were 98%, 100%, 95.4%, 100%, and 98.6% for INH, respectively. Specificity, sensitivity, PPV, NPV, and agreement for RIF were 96.3%, 88.2%, 88.2%, 96.3%, and 94.4%, respectively. Results in the study were obtained on average 10.9 ± 3.1 days in Phase I and 9.8 ± 2.2 days in Phase II. Conclusion: CVDA can be performed for drug susceptibility testing in developed and developing countries. In addition, further studies with larger sample size are needed for evaluation of this method.
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/95989
Coban, Ahmet Yilmaz; Alakbarova, Gumral; Satti, Luqman; Tayyab, Nadia; Zaman, Gohar; et al.; Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study; Medknow Publications; International Journal of Mycobacteriology; 7; 4; 10-2018; 310-314
2212-5531
2212-554X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/95989
identifier_str_mv Coban, Ahmet Yilmaz; Alakbarova, Gumral; Satti, Luqman; Tayyab, Nadia; Zaman, Gohar; et al.; Crystal violet decolorization assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates: A multicenter study; Medknow Publications; International Journal of Mycobacteriology; 7; 4; 10-2018; 310-314
2212-5531
2212-554X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4103/ijmy.ijmy_141_18
info:eu-repo/semantics/altIdentifier/url/http://www.ijmyco.org/article.asp?issn=2212-5531;year=2018;volume=7;issue=4;spage=310;epage=314;aulast=Coban
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Medknow Publications
publisher.none.fl_str_mv Medknow Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842981056994607104
score 12.48226

Publicaciones similares